<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Carcinoembryonic antigen-related cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule 1 (CEACAM1) is known to be downregulated at the transcriptional level in <z:mpath ids='MPATH_270'>adenoma</z:mpath> and <z:mp ids='MP_0002038'>carcinoma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Recent reports have shown that CEACAM1 is overexpressed at protein level in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and correlated with clinical stage </plain></SENT>
<SENT sid="2" pm="."><plain>The reason why <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells re-expressed CEACAM1 remains unclear </plain></SENT>
<SENT sid="3" pm="."><plain>The aim of our study was to clarify the implication of CEACAM1 re-expression in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Immunohistochemical analyses were conducted with CEACAM1 long (CEACAM1-L) or short (CEACAM1-S) cytoplasmic domain-specific antibodies on clinical samples from 164 patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The risk factors for <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> and survival were calculated for clinical implication of CEACAM1 re-expression </plain></SENT>
<SENT sid="6" pm="."><plain>Invasion chamber and wound healing assays were performed for the effect of CEACAM1 expression on invasion and migration of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells </plain></SENT>
<SENT sid="7" pm="."><plain>CEACAM1-L and CEACAM1-S stained with greater intensity at the invasion front than at the <z:chebi fb="2" ids="8069">luminal</z:chebi> surface of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Differences between the long and short cytoplasmic isoform expression levels were observed at the invasion front </plain></SENT>
<SENT sid="9" pm="."><plain>Multivariate analysis showed that CEACAM1-L dominance was an independent risk factor for lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>, hematogenous <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> and short survival </plain></SENT>
<SENT sid="10" pm="."><plain>The Kaplan-Meier evaluation demonstrated that CEACAM1-L dominance was associated with shorter survival time (p &lt; 0.0001) </plain></SENT>
<SENT sid="11" pm="."><plain>In the invasion chamber and wound healing assays, CEACAM1-L promoted invasion and migration </plain></SENT>
<SENT sid="12" pm="."><plain>Re-expression of CEACAM1 is observed at the invasion front of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>CEACAM1-L dominance is associated with <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> and shorter survival of the patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="14" pm="."><plain>CEACAM1-L dominance is important for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells invasion and migration </plain></SENT>
</text></document>